Ascendis’s Yorvipath Approved By FDA For Hypoparathyroidism But US Launch Delayed

Yorvipath Will Fill Gap Left By Takeda’s Natpara

 
• By Jessica Merrill
  
Ascendis' cleared the US regulatory hurdle for Yorvipath • Source: Shutterstock

More from New Products

More from Scrip